Zenalb – 20 is a sterile 20% aqueous solution of albumin and produced from human plasma. All donor omnadren vs sustanon plasma tested approved methods and does not contain antibodies to HBsAg and HIV – 1, HIV – 2 and HCV
omnadren vs sustanon hyperoncotic protein solution and administered intravenously increases circulating plasma volume through diffusion from the interstitial fluid space (in provided that the volume of the latter in the normal range or increased). The duration of this effect can vary from patient to patient. In some patients, the increase in plasma volume can be maintained for several hours. Albumin is also a transport protein, binding and transporting in the bloodstream hormones, enzymes, medicinal products.The average half-life of albumin, albumin is 19 days. Elimination takes place with the participation of intracellular lysosomal proteases. In healthy volunteers, at least 10% of the intravenously administered albumin derived from the vascular bed during the first 2 hours after infusion. However, patients who are in critical condition, may lose significant amounts of albumin, and its exit velocity of the vascular bed is unpredictable.
- in treatment of hypovolemic shock;
- for the treatment and prophylaxis of hypovolemia and hypoproteinemia:
- with extensive surgery, sepsis, acute adult respiratory distress syndrome;
- the removal of body fluids, protein-rich – ascites, pleural effusion;
- transfusion of large amounts of unfrozen washed erythrocytes;
- in the treatment of hemolytic disease of the newborn in order to reduce the level of free bilirubin in the blood (therapeutic plasma exchange);
- acute liver failure to maintain oncotic pressure of plasma, and an excess amount of binding of free bilirubin in the blood plasma;
- for preoperative hemodilution (to obtain additional blood volume to fill the heart-lung machine during surgery coronary bypass surgery);
- to enhance the therapeutic response in patients with acute nephritis are resistant to treatment with steroids or cyclophosphamide;
- the development of shock or hypotension in patients during hemodialysis. Contraindications
- Hypersensitivity to albumin or other components of the drug;
- chronic heart failure in the phase of decompensation;
- pulmonary edema;
- severe anemia;
Zenalb – 20 should be used with caution in patients with chronic renal failure, chronic heart failure in the phase of compensation, chronic compensated anemia, hypertension, esophageal varices, hemorrhagic diathesis, thrombosis, continuing internal bleeding, patients with senile and infants .
Use during pregnancy and lactation
Safety Zenalb drug – using 20 pregnant women in controlled clinical trials has not been studied. Available clinical experience with albumin does not give reason to expect any harmful effects on the course of pregnancy, the fetus or newborn, since human albumin is a normal component of human blood plasma.
Influence Zenalb – 20 on the reproductive function in animals have not studied.
Dosing and Administration
The concentration of the drug, the dose and infusion rate should be selected individually in each case.
The dose required for administration depend on the body weight, the severity of the disease or injury and the continued loss of protein and fluids. To determine the required dose should evaluate the adequacy of circulating blood volume and not plasma albumin levels.
For Zenalb – 20 single dose of 100 mL.
Zenalb – 20 is administered intravenously. The rate of infusion should be adjusted depending on the condition of the patient and indications.
The recommended rate of administration for patients with normal circulating blood volume is 1 – 2 mL / min (60 – 120 ml / hour). Patients with severe hypovolemia Zenalb -20 should be administered at a rate of 120 ml / hour. The solution may be administered by infusion using a suitable kit for intravenous administration with the filter.
Dose set individually, taking into account the indications of clinical status and body weight of the patient. The recommended single dose of from 0.5 to 1.0 g / kg.
In normal albumin 20% infusion side effects are minimal and can be reduced, mainly nausea, vomiting, chills, increased salivation and hyperthermia. There may be pain in the lumbar region, allergic reactions, urticaria, transient mild to severe anaphylactic shock. When they occur, the infusion should be stopped and implement a range of therapeutic measures against this reaction. Treatment of patients with hypovolemia may lead to hemodilution, which lasts for several hours.
In cases where the dose and infusion rate too high or does not match the patient’s circulatory system, may develop fluid overload and specific to her symptoms overload the cardiovascular system (shortness of breath, swelling of the jugular veins, headache). It is also possible increase in blood and / or central venous pressure, the development of pulmonary edema.
At the first symptoms overload the cardiovascular system, stop administration of the drug and to establish permanent control circulatory parameters. According to the testimony – symptomatic therapy. There are no specific antidotes.
Interaction with other medicinal products
should not be mixed Zenalb – 20 with other drugs.
During the infusion should be carefully observed for the clinical condition of the patient to prevent fluid overload. Signs of dysfunctions of the circulatory and respiratory systems should be monitored during and after treatment Zenalbom – 20. Selection and screening blood donors as well as heat treatment of the preparation at 60 ° C for 10 h virtually eliminate the risk of infection by viruses contained in blood.However, to completely eliminate the risk of contracting infection by viruses contained in the blood can not. In Zenalb – 20 should not add other medications.
Before infusion Zenalb – 20 should be warmed to room temperature.
Before use, each vial should be carefully examine. Muddy or freezes solutions and partially used vials must be discarded.
After the puncture caps required dose should be administered within 3 hours or immediately if it is a small amount.
Effects on ability to drive a car:
Influences Zenalba – 20 on the ability to drive or operate machines have been identified with.
Solution for Infusion 20%, 50 ml or 100 ml vial of colorless glass (type I Heb. F), rubber stoppers out of halobutyl rubber with aluminum lacquered run-and polypropylene screw cap.
The bottle with the drug, along with instructions for use in a carton box.
Do not use beyond the expiration date.
In the dark place at a temperature of 2 -. 25 ° C in the original package
Do not refrigerate.
Keep out of the reach of children.